Future Cannabis Strategies Europe hits London in January 2019
he event heavily focuses on identifying opportunities within the European market place and spotlights regulation to ensure producers and retailers of cannabinoid products operate legally.
Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
A review of the literature indicates that significant progress has been made since Dr. Ethan B. Russo’s landmark paper, just ten years ago (February 2, 2004). Investigation at that time suggested that cannabinoids can block spinal, peripheral and gastrointestional mechanisms that promote pain in headache, fibromyalgia, irritable bowel syndrome and muscle spasm. Further research and especially, clinical trials will further demonstrate the usefulness of medical cannabis. As legal barriers fall and scientific bias fades this will become more apparent.
Canadian medical marijuana patients are turning to nurses for help.
Nurses are on the frontline with cannabis these days because we are situated closest to the patients